[go: up one dir, main page]

MA35674B1 - Derives de chromone, leur procede de preparation et leurs applications therapeutiques - Google Patents

Derives de chromone, leur procede de preparation et leurs applications therapeutiques

Info

Publication number
MA35674B1
MA35674B1 MA34616A MA34616A MA35674B1 MA 35674 B1 MA35674 B1 MA 35674B1 MA 34616 A MA34616 A MA 34616A MA 34616 A MA34616 A MA 34616A MA 35674 B1 MA35674 B1 MA 35674B1
Authority
MA
Morocco
Prior art keywords
preparation
therapeutic applications
chromone derivatives
chromone
derivatives
Prior art date
Application number
MA34616A
Other languages
English (en)
Inventor
Thierry Imbert
Jean-Pierre Rieu
Jean-François Patoiseau
Pierre Sokoloff
Ludovic Leriche
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA35674B1 publication Critical patent/MA35674B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention porte sur des dérivés de chromone, sur leur préparation, sur leurs compositions pharmaceutiques et sur leur application comme ligands dopaminergiques d3 en tant que médicaments pour des troubles du système nerveux central.
MA34616A 2009-09-01 2012-02-09 Derives de chromone, leur procede de preparation et leurs applications therapeutiques MA35674B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0955944A FR2949465B1 (fr) 2009-09-01 2009-09-01 Derives chromones, leur procede de preparation et leurs applications therapeutiques
PCT/IB2010/053895 WO2011027289A1 (fr) 2009-09-01 2010-08-31 Dérivés de chromone, leur procédé de préparation et leurs applications thérapeutiques

Publications (1)

Publication Number Publication Date
MA35674B1 true MA35674B1 (fr) 2014-12-01

Family

ID=41403421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34616A MA35674B1 (fr) 2009-09-01 2012-02-09 Derives de chromone, leur procede de preparation et leurs applications therapeutiques

Country Status (31)

Country Link
US (1) US8546402B2 (fr)
EP (1) EP2470520B1 (fr)
JP (1) JP5786229B2 (fr)
KR (1) KR101663635B1 (fr)
CN (1) CN102482251B (fr)
AR (1) AR078114A1 (fr)
AU (1) AU2010290871B2 (fr)
BR (1) BR112012003741B1 (fr)
CA (1) CA2771061C (fr)
CL (1) CL2012000516A1 (fr)
CO (1) CO6491096A2 (fr)
DK (1) DK2470520T3 (fr)
ES (1) ES2428751T3 (fr)
FR (1) FR2949465B1 (fr)
GE (1) GEP20146080B (fr)
HR (1) HRP20130832T1 (fr)
IL (1) IL217729A (fr)
MA (1) MA35674B1 (fr)
MX (1) MX2012002543A (fr)
MY (1) MY162345A (fr)
NZ (1) NZ597930A (fr)
PL (1) PL2470520T3 (fr)
PT (1) PT2470520E (fr)
RU (1) RU2545214C2 (fr)
SG (1) SG178198A1 (fr)
SI (1) SI2470520T1 (fr)
TN (1) TN2012000049A1 (fr)
TW (1) TWI510483B (fr)
UA (1) UA109260C2 (fr)
WO (1) WO2011027289A1 (fr)
ZA (1) ZA201200770B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2313406B1 (fr) 2008-08-05 2015-02-25 Boehringer Ingelheim International GmbH Napththyridines substituées par 4-diméthylaminophényle et leur utilisation en tant que médicament
KR101727876B1 (ko) 2009-05-13 2017-04-17 길리애드 파마셋 엘엘씨 항바이러스 화합물
BR112012018865A2 (pt) 2010-01-29 2016-04-12 Boehringer Ingelheim Int naftiridinas substituídas e seu uso como inibidores de quinase syk
EA024845B1 (ru) 2011-07-26 2016-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хинолины и их применение в качестве лекарственных средств
KR20190075142A (ko) 2011-09-16 2019-06-28 길리애드 파마셋 엘엘씨 Hcv 치료 방법
HUE047777T2 (hu) 2013-01-31 2020-05-28 Gilead Pharmasset Llc Két vírusellenes vegyület kombinációs készítménye
EP3650014B1 (fr) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Formulation de combinaison de deux composés antiviraux
HUE036035T2 (hu) * 2013-12-13 2018-06-28 Pf Medicament Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra
JP7250787B2 (ja) * 2017-11-03 2023-04-03 ピエール、ファーブル、メディカマン 統合失調症の治療
CA3093445A1 (fr) 2018-03-08 2019-11-28 Incyte Corporation Composes d'aminopyrazine diol utilises comme inhibiteurs de pi3k-.gamma.
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
IL301225A (en) * 2020-09-09 2023-05-01 Aurigene Oncology Ltd Heterocyclic compounds as CBP/EP300 bromodomain inhibitors
CN112220782B (zh) * 2020-11-11 2021-08-20 中国人民解放军军事科学院军事医学研究院 1,2,4-三甲氧基苯在防治创伤后应激障碍中的应用
JP7725617B2 (ja) 2021-05-21 2025-08-19 ギリアード サイエンシーズ， インコーポレイテッド ジカウイルス阻害剤としての五環式誘導体
JP7723119B2 (ja) 2021-05-21 2025-08-13 ギリアード サイエンシーズ， インコーポレイテッド ジカウイルス感染症の治療のための四環系化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089497A (en) * 1990-09-20 1992-02-18 Warner-Lambert Company Substituted piperazines as central nervous system agents
DE4233963A1 (de) * 1992-10-08 1994-04-14 Schwabe Willmar Gmbh & Co Neue Benzopyranone, Verfahren zu ihrer Herstellung und Verwendung
RU2320656C2 (ru) * 2002-07-04 2008-03-27 Шварц Фарма Аг Производные гетероаренкарбоксамида, способ их получения, фармацевтическая композиция на их основе и применение
EP1683790A1 (fr) * 2005-01-24 2006-07-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dérivés de 3,4-dihydro-2-naphtamide comme ligands selectifs de la dopamine D3
HUP0700605A3 (en) * 2005-02-18 2008-02-28 Arpida Ag Novel processes for the preparation of a benzofuran
FR2903986A1 (fr) * 2006-07-21 2008-01-25 Pierre Fabre Medicament Sa Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique

Also Published As

Publication number Publication date
KR20120060835A (ko) 2012-06-12
FR2949465A1 (fr) 2011-03-04
EP2470520B1 (fr) 2013-07-17
AU2010290871A1 (en) 2012-02-16
RU2012106743A (ru) 2013-10-10
JP2013503848A (ja) 2013-02-04
UA109260C2 (uk) 2015-08-10
CA2771061C (fr) 2015-06-02
JP5786229B2 (ja) 2015-09-30
HRP20130832T1 (en) 2013-10-11
RU2545214C2 (ru) 2015-03-27
SG178198A1 (en) 2012-03-29
PT2470520E (pt) 2013-10-02
MY162345A (en) 2017-06-15
CN102482251A (zh) 2012-05-30
CA2771061A1 (fr) 2011-03-10
KR101663635B1 (ko) 2016-10-10
CO6491096A2 (es) 2012-07-31
TN2012000049A1 (en) 2013-09-19
NZ597930A (en) 2013-09-27
TWI510483B (zh) 2015-12-01
IL217729A0 (en) 2012-03-29
MX2012002543A (es) 2012-06-25
PL2470520T3 (pl) 2013-10-31
WO2011027289A1 (fr) 2011-03-10
EP2470520A1 (fr) 2012-07-04
HK1170724A1 (en) 2013-03-08
GEP20146080B (en) 2014-04-25
US20120157463A1 (en) 2012-06-21
ZA201200770B (en) 2012-10-31
CL2012000516A1 (es) 2012-08-31
DK2470520T3 (da) 2013-08-26
FR2949465B1 (fr) 2011-08-12
CN102482251B (zh) 2015-01-28
BR112012003741B1 (pt) 2021-06-22
TW201111369A (en) 2011-04-01
SI2470520T1 (sl) 2013-10-30
ES2428751T3 (es) 2013-11-11
US8546402B2 (en) 2013-10-01
AR078114A1 (es) 2011-10-12
AU2010290871B2 (en) 2014-06-26
IL217729A (en) 2015-09-24

Similar Documents

Publication Publication Date Title
MA35674B1 (fr) Derives de chromone, leur procede de preparation et leurs applications therapeutiques
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA30630B1 (fr) Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique.
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
MA39783B1 (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
TN2014000301A1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2008152093A3 (fr) Diaminopyrimidines en tant que modulateurs du récepteur ep2
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA34474B1 (fr) Agonistes de gpr40
EP2666471A4 (fr) Composition pharmaceutique pour la traitement de la rate et de l'estomac, ainsi que procédé de préparation de cette composition
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
EP2606887A4 (fr) Diindolylméthane, ses précurseurs et dérives utilisés dans la préparation de médicaments pour le traitement de maladies du foie
FR2981933B1 (fr) Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
MA20150350A1 (fr) Dérivés isoxazolidine
EP2789337A4 (fr) Composition pharmaceutique comprenant des dérivés de pyridinol bicycliques pour la prévention ou le traitement de maladies causées par l'angiogenèse